Novavax (NVAX) stock

Disease vaccines , market cap $1.6B

Vaccines that prevent infectious diseases

Worth $1.6B

$10.20

-6.34%

As of Tuesday's close · Live for Pro members at the open

Why is NVAX down?

Down 6.3% today, more than its biotech peers' 1.4%; no story names it yet.

Fell on Nov 5

Down 8% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6%.

Its Nov 5 results: total revenue was $68M, from $70M a year before; licensing, royalties and other revenue was $43M, down 25%. It fell 8% on Nov 5.

Sources: Price history, Nov 5, 2026; Company release, Nov 5, 2026

Tell me next time NVAX moves

Free account, no card. An optional alert when NVAX moves or its score changes.

Or see it live, free until Thursday morning. No account.

1 more reason, free with an account →The other side, the timeline, and its peers, for Pro members.

Why NVAX still beats the market over a year

Up 53% over the year to Nov 9 while the S&P 500 rose 12%; down 8% on Nov 5.

3 reasons, from its filings, with the timeline and its peers, for Pro members.

Quality Score

Below Average

In its industry

#129of 281

Biotech

Checks firing

3of 14

Trending up

From 52-week high

-23.8%

under its best in a year

NVAX's Quality Score was unchanged on Tue, Nov 10, at 1.

Follow NVAX's news. Pro members can get an alert when Novavax files news, and see its trials, share raises, and its CEO's filings.

Get an alert when NVAX files newsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2027“…their intent to initiate a U.S. Phase 3 influenza-COVID-19 combination vaccine trial in 2027 to support…”Trial start · SEC filing · Nov 5

Cash$622M, about 10 quarters (2.5 years) at the last year's spendingOn Sep 30

Key facts on NVAX

Key facts on NVAX
Since its Nov 2021 high	Down 95% sales $1.15B → $411.6M a year
Latest filing	8-K, Nov 5 Reported its quarterly results

1 more reason behind NVAX's 1, free with an account →4 more reasons behind NVAX's 1, for Pro members.

NVAX in the news

TodayNo story names it yet.

Cash$622M, about 10 quarters (2.5 years) at the last year's spendingOn Sep 30

NVAX catalysts

Coming up

After its last 4 reports it closed +6.3% on average, higher 3 of 4 times.

46 past catalysts since 2021, with sizes and sources, for Pro members.

What's next for NVAX, and how long its cash lasts

Next step the company has named

2027“Sanofi confirms their intent to initiate a U.S. Phase 3 influenza-COVID-19 combination vaccine trial in 2027 to support U.S. approval”Trial start · SEC filing · Nov 5

What it means: when a trial begins, or reaches the stage the company named.

For Pro members: 53 filings.

Cash runway Sep 30 balance sheet

About 10 quarters

$622M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: the amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

Get an alert when John Jacobs buys or sells

For Pro members: every trade, and John Jacobs’s 7 filings and quotes.

Get an alert when NVAX files newsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why NVAX scores 1

Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means

+3Chart checks 3 of 14 firing right now, one point each
+2Long-term trend above a rising 200-⁠day average

Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth subtractsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
News adds

No effect today: Run-up, Size, Dilution, and Persistence.

What every line is worth, and the reason behind it, on NVAX and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:29 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How NVAX ranks in Biotech

NVAX is #129 of 281 by Quality Score.

How NVAX ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	NTLAIntellia Therapeutics		Open for its score
	NUVBNuvation Bio		Open for its score
	OABIOmniAb		Open for its score
	OBXObsidian Therapeutics		Open for its score
129	NVAXNovavax	3/14	1

When does NVAX report earnings, and what happens after?

Expected to report Thu Feb 25, before the open (in 107 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What NVAX reported on Nov 5, 2026

The quarter

Sales of $68.3M, 3% less than a year ago; a loss of $0.19 a share, from $1.25.

“Licensing royalties and other revenue of $43 million in the third quarter of 2026 were 25% lower than the same period in 2025 driven primarily by a $42 million reduction year-over-year in research and development (R&D) reimbursement revenue as Novavax nears completion of its support of Sanofi Nuvaxovid clinical support for postmarketing commitments.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

Where the quarter's sales came from
Line	Q3 2026	Q2 2026	Q3 2025
By product
Licensing, Royalties, and Otherdown 25%	$42.6M45%	$37.8M67%	$57M68%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)

5 more lines, for Pro members.

The outlook

The outlook the company gave, by period
Measure	Figure
Full year 2026
Adjusted total revenue	$400Mraised

Figures as filed (SEC filing, Nov 5)

5 more outlook lines, for Pro members.

The numbers

Market value: $1.6B; today
Sales: $412M; down 61.3% on the year

Sales grew 19% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 15% a year over 5 years.

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on NVAX: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+15.6%+0.5%-8.2%

May 6Aug 6Nov 5

Reported	When	Gap	Reaction	5 days
Nov 5, 2026Before open	Before open	-2.9%	-8.2%	not yet
Aug 6, 2026Before open	Before open	+1.6%	+0.5%	+3.4%
May 6, 2026Before open	Before open	+5.7%	+15.6%	+18.8%

NVAX closed higher after 3 of its last 4 reports.

All 4 reports, and NVAX's Quality Score going into each

NVAX sales and profit by year

Sales and profit by year

Sales grew in four of the last seven years, to $1.1B in 2025. It turned a profit in 2025 after a loss in 2024.

NVAX has 3 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on NVAX, and all 14 on every stock.Get in free →

NVAX RSI today: 47.7, below its 50-day, above its 200-day

Not scored

RSI 47.7, MACD below signal, below its 50-day, above its 200-day. Not scored.13 readings

The deep dive on NVAX

What it does and how it makes money7 findingsLicensing, Royalties, and Other made up 39% of its revenue in fiscal 2025 ($438M of $1.12B), against 69% in fiscal 2024; product sales 61%.SEC filing · Feb 26, 2026"COVID/Influenza: We have more than 40 combined patents and pending applications in the US and internationally related to compositions and methods for inducing immune responses against both influenza and coronaviruses that will expire beyond 2042 when issued." (10-K for fiscal 2025)SEC filing · Feb 26, 2026
Where it stands2 findingsFor Pro members2 findings on where NVAX stands: its cash, debt, and share count, for Pro members
What changed in its filings1 findingGovernment of Canada made up 51% of its revenue in fiscal 2025; Sanofi made up 36%, down from 68% in fiscal 2024.SEC filing · Feb 26, 2026
Who holds and trades it1 findingFor Pro members1 finding on who holds and trades NVAX, for Pro members

8 more findings on NVAX, each with its source, for Pro members.

NVAX's officers and directors

Officers and directors with a Form 4 in the last 12 months.

John C. JacobsPresident and CEO · no trades on file
James Patrick KellyEVP, CFO and Treasurer · no trades on file
Elaine O'HaraEVP, Chief Strategy Officer · no trades on file
Mark J. CaseyEVP, Chief Legal Officer · no trades on file
Ruxandra Draghia-AkliEVP, Research & Development · no trades on file
Charles W. NewtonDirector · no trades on file
David M. MottDirector · no trades on file
Gregg H. AltonDirector · no trades on file

5 more officers and directors file at NVAX.

See insider trades by person

Which ETFs hold NVAX?

In ETFs: NVAX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Novavax

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

749 employeesGaithersburg, MDnovavax.com

What Novavax says it competes with

“The vaccine market is intensely competitive, characterized by rapid technological progress.”

From its annual report, SEC filing · Feb 26, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on NVAX and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn NVAX's score around: 8 things
3 more filings explained, a plain line each
Real-⁠time prices, no delay

See NVAX's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: NVAX's Quality Score is 1 (Below Average), #129 of 281 in Biotech.

What does NVAX's Quality Score say?

NVAX scores 1 today, which Breakaway calls Below Average. It is #129 of 281 in Biotech by Quality Score, with 3 of 14 chart checks firing. Down 8% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6%. Cash lasts about 10 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is NVAX's Quality Score?

NVAX scores 1 today, which Breakaway calls Below Average (0 to 5). That is #129 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind NVAX's 1.

When does NVAX report earnings?

Expected to report Thu Feb 25, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. NVAX closed higher after 3 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.